Intersect ENT (XENT) Reaches New 52-Week High and Low at $42.20

Intersect ENT (NASDAQ:XENT)’s share price hit a new 52-week high and low during trading on Friday . The stock traded as low as $42.20 and last traded at $42.05, with a volume of 155230 shares trading hands. The stock had previously closed at $41.55.

Several brokerages have recently commented on XENT. Berenberg Bank began coverage on Intersect ENT in a research note on Friday. They issued a “buy” rating on the stock. BidaskClub raised Intersect ENT from a “hold” rating to a “buy” rating in a research note on Tuesday, April 17th. ValuEngine raised Intersect ENT from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Zacks Investment Research raised Intersect ENT from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. Finally, Guggenheim reissued a “buy” rating on shares of Intersect ENT in a research note on Thursday, March 1st. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Intersect ENT has an average rating of “Buy” and a consensus target price of $33.38.

How to Become a New Pot Stock Millionaire

The company has a market capitalization of $1,238.40, a PE ratio of -74.55 and a beta of 0.75.



Intersect ENT (NASDAQ:XENT) last posted its earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.06. Intersect ENT had a negative return on equity of 14.40% and a negative net margin of 16.99%. The firm had revenue of $29.53 million for the quarter, compared to analyst estimates of $29.45 million. analysts expect that Intersect ENT will post -0.61 EPS for the current year.

In related news, insider Lisa D. Earnhardt sold 15,000 shares of the stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $39.59, for a total transaction of $593,850.00. Following the transaction, the insider now owns 499,683 shares of the company’s stock, valued at approximately $19,782,449.97. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Richard E. Kaufman sold 958 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $37.21, for a total value of $35,647.18. Following the transaction, the chief operating officer now directly owns 87,512 shares in the company, valued at approximately $3,256,321.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 84,457 shares of company stock worth $3,153,971. 13.70% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. MetLife Investment Advisors LLC purchased a new stake in Intersect ENT during the 4th quarter worth about $370,000. Wolverine Trading LLC purchased a new stake in Intersect ENT during the 4th quarter worth about $341,000. Elkfork Partners LLC purchased a new stake in Intersect ENT during the 4th quarter worth about $237,000. TIAA CREF Investment Management LLC increased its holdings in Intersect ENT by 7.7% during the 4th quarter. TIAA CREF Investment Management LLC now owns 137,428 shares of the medical equipment provider’s stock worth $4,453,000 after purchasing an additional 9,792 shares during the period. Finally, Teachers Advisors LLC increased its holdings in Intersect ENT by 333.9% during the 4th quarter. Teachers Advisors LLC now owns 288,732 shares of the medical equipment provider’s stock worth $9,355,000 after purchasing an additional 222,195 shares during the period. Institutional investors own 84.49% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Intersect ENT (XENT) Reaches New 52-Week High and Low at $42.20” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://stocknewstimes.com/2018/04/22/intersect-ent-xent-reaches-new-52-week-high-and-low-at-42-20.html.

About Intersect ENT

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply